Navigation Links
Rheumatoid arthritis patients not taking their medications as prescribed
Date:5/30/2013

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis (RA) patients had an overall adherence rate to prescribed oral medications at 80% or greater. Findings published today in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that less than two thirds of medication regimens for non-biologic disease modifying anti-rheumatic drugs (DMARDs) were correctly followed by RA patients.

According to ACR estimates, more than one million U.S. adults experience inflammation, pain, tenderness and swelling of the joints caused by RA. While there have been advances in RA treatmentsbiologic therapies such as the tumor necrosis factor (TNF) inhibitors adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade)oral DMARDS, namely methotrexate, remain the gold standard for treating those with RA. In fact, previous research has shown that biologics are more effective when taken with methotrexate, but patients must follow the prescribed medicine regimens to realize the full benefits.

For the present study, Drs. Christian Waimann, Maria Suarez-Almazor and colleagues from The University of Texas MD Anderson Cancer Center, in Houston enrolled 107 RA patients in a two-year study that electronically monitored their intake of oral RA medications. Measures of DMARD adherence were:

  • Doses taken as prescribed: Percentage of days or weeks for methotrexate or prednisone in which the patient took the correct dose as prescribed
  • Underdosing: Percentage of days or weeks in which the patient took fewer doses than prescribed
  • Overdosing: Percentage of days or weeks that the patient took more doses than prescribed

Of those who participated, 87% were female with a mean disease activity of 8 years. The RA patient group was ethnically diverse with 65% Hispanic, 19% African-American and 16% Caucasian. Educational status was low with 45% not completing high school and 67% having incomes less than $20,000.

RA patients who took their medications as prescribed were considered adherent64% for DMARD therapy and 70% for prednisone. Only 21% of participants adhered to their DMARD therapy and 41% correctly took prednisone at least 80% of the time. Patients who took their medications as prescribed showed significantly lower disease activity scores (DAS28 at 3.3) throughout the study period compared to those who were less adherent (DAS28 at 4.1). Increases in radiological damage score were also higher in RA patients who were non-adherent.

Researchers report that adherence to oral DMARDs and steroid therapy in RA patients with RA was low, ranging from 58% to 71%, but patients who had better mental health status and were not widowed or separated were more likely to adhere to their medication regimen. "Our study is the first to measure drug adherence in RA patients over the long-term, and emphasizes the importance of following the prescribed regimen to manage their disease," concludes Dr. Suarez-Almazor. "Physicians should work with patients to understand their reasons for non-adherence and discuss the importance of taking medications as prescribed to control RA symptoms and prevent disease progression."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Women Who Smoke May Have Higher Risk for Rheumatoid Arthritis
2. Even a few cigarettes a day increases risk of rheumatoid arthritis
3. Medications used to treat rheumatoid arthritis may affect abortion rate in women
4. Research find links between lifestyle and developing rheumatoid arthritis
5. Rheumatoid Arthritis Can Be Costly
6. Wide disparities in access to latest rheumatoid arthritis drugs across Europe
7. Salty Diet Might Help Trigger MS, Rheumatoid Arthritis
8. Newer Rheumatoid Arthritis Drugs Dont Seem to Increase Risk of Shingles
9. Sunshine Linked to Lower Rheumatoid Arthritis Risk: Study
10. Researchers uncover genes role in rheumatoid arthritis, findings pave way for new treatments
11. Newly approved oral medication slows rheumatoid arthritis joint damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... This week ... claims firms in Texas. Founded by Bill Voss, the firm grew quickly and has ... and a half of helping clients get the money they deserve from their insurance ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Earlier this ... authority on the use of health IT to create efficiencies in healthcare information exchange ... held its 2017 Summer Forum which featured keynote addresses by Donald W. ...
(Date:8/23/2017)... ... August 23, 2017 , ... The Stevie® Awards have announced the winners of the Best ... world’s premier business awards competition. , Nominees in the 2017 IBAs were not able to ... system based on the total number of awards won in the IBAs with a Gold ...
(Date:8/23/2017)... ... August 23, 2017 , ... Cirrus Medical Staffing, ... new website, http://www.cirrusmedicalstaffing.com . The new site pairs a robust job search ... professionals who are traveling on short-term assignments to healthcare facilities around the country. ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc. announced today that its fully owned USA ... York City Office in Yonkers, New York ... (TWO 2 ) homecare therapy. This new East Coast location has ... under the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New ...
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology: